IHC - Microsatellite Instability for Colorectal Carcinoma MSH-2

The IHC – Microsatellite Instability (MSH2) test for Colorectal Carcinoma is a specialized immunohistochemistry (IHC) diagnostic test used to detect MSH2 protein expression in colorectal cancer tissue samples. MSH2 is one of the essential DNA mismatch repair (MMR) proteins responsible for correcting DNA replication errors. Loss of MSH2 protein expression may indicate microsatellite instability (MSI) and can suggest an increased likelihood of Lynch syndrome, a hereditary condition linked to colorectal and other cancers.

Microsatellite instability occurs when the DNA repair system fails to correct replication mistakes, causing genetic instability in tumor cells. This condition is clinically significant because MSI-positive colorectal cancers often have unique biological behavior and may respond better to certain treatments, including immunotherapy.

The MSH2 test is typically performed as part of a comprehensive mismatch repair panel along with MLH1, MSH6, and PMS2 to provide a complete microsatellite instability profile.

Benefits of the Test

The MSH2 MSI test provides several important clinical benefits:

• Detects loss of MSH2 protein expression
• Identifies microsatellite instability in colorectal tumors
• Helps screen for Lynch syndrome
• Supports accurate colorectal cancer classification
• Assists in selecting targeted treatment options
• Helps evaluate hereditary cancer risk

This test is essential for precision oncology and long-term cancer management.

Why Doctors Recommend This Test

Doctors recommend the MSH2 IHC test for patients diagnosed with colorectal carcinoma or when hereditary cancer syndromes are suspected.

It is commonly advised for:

• Newly diagnosed colorectal cancer patients
• Patients with family history of colorectal or related cancers
• Early-onset colorectal cancer cases
• Suspected Lynch syndrome screening
• Advanced tumor molecular profiling

The results help oncologists make informed treatment decisions and guide recommendations for genetic counseling.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected colorectal tissue biopsy or surgical tumor samples.

Normal Reporting Time

The normal turnaround time for the MSH2 IHC test is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with colorectal carcinoma
• Individuals with suspected Lynch syndrome
• Patients with family history of hereditary cancers
• Cases needing microsatellite instability evaluation
• Oncology patients requiring personalized treatment planning

The IHC MSH2 test is an essential diagnostic tool in colorectal cancer care. It helps identify DNA repair defects, assess inherited cancer risk, and guide advanced treatment strategies. Early detection improves outcomes and supports preventive family screening.